The Future of Chemotherapy: Nanotechnology, AI, and Precision Medicine

Cherdak Mandava*

Jackson Memorial Hospital, Sylvester Comprehensive Cancer Center and the Department of Radiation Oncology, University of Miami, Miami, Florida, United States

Corresponding Author*

Cherdak Mandava

Jackson Memorial Hospital, Sylvester Comprehensive Cancer Center and the Department of Radiation Oncology, University of Miami, Miami,

Florida, United States

E-mail: cherdak.m856@gmail.com

Copyright: ©2025 Mandava C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 Received:
 13-Aug-2025,
 Manuscript
 No.
 OCCRS-25-169505;
 Editor assigned:

 15-Aug-2025,
 PreQC No:
 OCCRS-25-169505 (PQ);
 Reviewed:
 25-Aug-2025,

 Aug-2025,
 QC
 No.
 OCCRS-25-169505 (Q);
 Revised:
 27-Aug-2025,

 Manuscript
 No.
 OCCRS-25-169505 (R);
 Published:
 31-Aug-2025,
 DOI:

 10.35248/2332-2594.22.10(4).001-004

Abstract

In recent years, immunotherapy has emerged as a revolutionary approach in the fight against cancer and autoimmune diseases. Unlike traditional treatments such as chemotherapy and radiation, which indiscriminately target both healthy and diseased cells, immunotherapy seeks to harness and reprogram the body's own immune system to recognize and eliminate pathological threats. This paradigm shift in medicine is not only transforming patient outcomes but also redefining our understanding of immunity itself.

Keywords: Immunotherapy • Cancer Treatment

Introduction

The immune system is a complex network of cells, tissues, and signaling molecules designed to defend the body against infections, malignancies, and foreign substances. It operates through two main arms: the innate immune system, which provides immediate but non-specific defense, and the adaptive immune system, which offers targeted and long-lasting protection. However, cancer cells and autoimmune disorders exploit vulnerabilities in this system. Tumors, for instance, can evade immune detection by suppressing immune responses or disguising themselves as normal cells. Autoimmune diseases, on the other hand, result from the immune system mistakenly attacking healthy tissues. Immune reprogramming refers to the deliberate modification of immune cells to enhance their ability to detect and destroy disease-causing agents. This can be achieved through genetic engineering, molecular signaling manipulation, or cellular re-education. The goal is to restore or amplify immune surveillance and response mechanisms that have been compromised [1].

One of the most prominent examples of immune reprogramming is CART cell therapy. In this approach, a patient's T cells are extracted, genetically modified to express chimeric antigen receptors (CARs) that target specific cancer antigens, and then re-infused into the body. These engineered cells can then seek out and destroy cancer cells with remarkable precision [2].

While cancer remains the primary focus of immunotherapy, immune reprogramming is also being explored for autoimmune diseases like lupus, rheumatoid arthritis, and multiple sclerosis. In these cases, the goal is to suppress or redirect immune responses that are attacking healthy tissues [3].

For example, researchers are investigating ways to reprogram regulatory T cells (Tregs) to restore immune tolerance and prevent autoimmune flare-ups. Similarly, dendritic cells—key antigen-presenting cells—can be re-engineered to modulate immune responses more effectively [4].

Researchers are also exploring switchable CAR-T cells, which can be turned on or off depending on the therapeutic need, offering greater control and safety. Additionally, combining immunotherapy with traditional treatments like chemotherapy or radiation is showing synergistic effects in clinical trials. The future of immunotherapy lies in precision medicine—developing treatments that are customized to a patient's genetic and immunological profile. Advances in CRISPR gene editing, nanotechnology, and AI-driven diagnostics are accelerating this shift [5].

Conclusion

Reprogramming the immune system is not just a scientific breakthrough it's a philosophical shift in how we approach disease. By empowering the body's natural defenses, immunotherapy offers a more intelligent, targeted, and potentially curative approach to some of the most challenging medical conditions. As research continues to unravel the intricacies of immune signaling and cellular behavior, the dream of personalized, effective, and safe immunotherapy is becoming a reality. The immune system, once a passive player in medicine, is now at the forefront of a new era in healthcare.

References

- Nauman, Muhammad, and Stephen Leslie. "Nonseminomatous testicular tumors." StatPearls (2023).
- Williamson, Sean R., et al. "The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel." *Histopathology* 70.3 (2017): 335-346.
- 3. Bulic- Jakus, Floriana, et al. "Teratoma: from spontaneous tumors to the pluripotency/malignancy assay." *Wiley Interdiscip Rev: Dev Biol.* 5.2 (2016): 186-209Shaffrey, Mark E., et al. "Maturation of intracranial immature teratomas: Report of two cases." *J Neurosurg.* 85.4 (1996): 672-676.
- Mahajan, Swati, et al. "World Health Organization classification of tumors of the central nervous system 5th Edition (WHO CNS5): what's new?" *Indian J Pathol Microbiol*. 65.Suppl 1 (2022): S5-S13.
- Packer, Roger J., Bruce H. Cohen, and Kathleen Cooney. "Intracranial germ cell tumors." *Oncologist* 5.4 (2000): 312-320

